Last edition
News about "Johnson and Johnson"
Johnson & Johnson Secures FDA Priority Review for Imaavy in Rare Blood Disorder
Johnson & Johnson moves closer to delivering a first-in-class treatment for Warm Autoimmune Haemolytic Anaemia with FDA Priority Review for Imaavy.
Johnson And Johnson | 28/04/2026 | By News Bureau
Johnson & Johnson Submits sBLA to US FDA for IMAAVY in Warm Autoimmune Hemolytic Anemia
Johnson & Johnson has filed a supplemental biologics application seeking US approval of IMAAVY (nipocalimab) for warm autoimmune hemolytic anemia, a rare disorder with no currently approved treatments.
Johnson And Johnson | 26/02/2026 | By News Bureau | 189
Simplified once-monthly schedule for RYBREVANT FASPRO matches bi-weekly efficacy, reduces clinic visits and maintains a strong safety profile.
Johnson And Johnson | 18/02/2026 | By News Bureau | 114
US Tariffs on EU Pharma Imports Threaten Drug Access and Innovation, GlobalData Warns
The US-EU trade deal has placed the pharmaceutical industry under significant fiscal strain, with consequences that extend beyond short-term financials, according to GlobalData, a leading data and analytics company.
Johnson And Johnson | 05/08/2025 | By Dineshwori | 273
Merck, BMS, Pfizer to Be Hit Hard by Looming Patent Cliff: Report Warns
Major pharmaceutical players, including Merck, Bristol Myers Squibb (BMS), Johnson and Johnson, Pfizer, and Novartis, are expected to experience significant revenue losses as several of their blockbuster drugs approach patent expirations, according to a new report by Research and Markets.
Johnson And Johnson | 28/07/2025 | By Dineshwori | 821
Johnson and Johnson Reports Over 18 Percent Jump in Q2 Earnings
Johnson and Johnson has reported its second-quarter 2025 results, with net earnings soaring 18.2 percent to USD 5.54 billion, up from USD 4.69 billion in the same period last year.
Johnson And Johnson | 17/07/2025 | By Dineshwori | 270
Global Topical Antibiotics Market Projected to Surpass USD 11 Billion by 2032
The global topical antibiotics market, valued at USD 6.42 billion in 2024, is expected to reach nearly USD 11.20 billion by 2032.
Johnson And Johnson | 14/07/2025 | By Dineshwori | 263
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy